Evidence map›Paper›PMID 41562289›Full record

ArticleMuscle & nerve2026

Efficacy of a K

Viktor Chanchykov, Sharon Iype, Marbella Quinonez, Fenfen Wu, Stephen Cannon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Viktor ChanchykovDepartment of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Sharon IypeDepartment of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Marbella QuinonezDepartment of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Fenfen WuDepartment of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Stephen CannonDepartment of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-8428-3690

Funding

Disease Pathogenesis and Modification for CaV1.1-Associated Hypokalemic Periodic ParalysisR01AR063182 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI STEPHEN C. CANNON · 2012 to 2026
$6.0M
Pathophysiology of Myotonia and Periodic ParalysisR01AR078198 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CANNON, STEPHEN C. · 2021 to 2025
$2.7M
NIAMS NIH HHS AR063182NIAMS NIH HHS AR078198NIAMS NIH HHS R01 AR063182NIAMS NIH HHS R01 AR078198
6 · The paper itself

Abstract

INTRODUCTION/

aimsEffective management remains lacking for recurrent episodes of acute weakness in hypokalemic periodic paralysis (HypoPP). We assessed the efficacy of a second-generation potassium channel agonist, XEN1101, to prevent and abort the low-K

methodsAn ex vivo contractility assay was used to interrogate the efficacy of XEN1101 for preserving contractile force and for enhancing recovery of force in the setting of a low-K

resultsThe acute loss of force for HypoPP muscle, triggered by a 2 mM K DISCUSSION: The K

Indexed as

CarbamatesHypokalemic Periodic ParalysisMuscle ContractionPhenylenediaminesPotassium ChannelsAnimalsCalcium Channels, L-TypeDisease Models, AnimalMaleMiceMice, TransgenicMuscle, SkeletalPotassiumCalcium Channels, L-TypeCarbamatesezogabinePhenylenediaminesPotassiumPotassium ChannelschannelopathyKCNQKv7 potassium channelmouse modelperiodic paralysisskeletal muscle

Identifiers

PMID41562289
PMCPMC12969960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.